[go: up one dir, main page]

NO981135L - Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser - Google Patents

Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser

Info

Publication number
NO981135L
NO981135L NO981135A NO981135A NO981135L NO 981135 L NO981135 L NO 981135L NO 981135 A NO981135 A NO 981135A NO 981135 A NO981135 A NO 981135A NO 981135 L NO981135 L NO 981135L
Authority
NO
Norway
Prior art keywords
tetrahydro
acid addition
addition salts
benzazepine compounds
benzazepine
Prior art date
Application number
NO981135A
Other languages
English (en)
Other versions
NO981135D0 (no
Inventor
Louis Brammer Hansen
Rolf Emil Amsler
Scott Eugene Mcgraw
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO981135L publication Critical patent/NO981135L/no
Publication of NO981135D0 publication Critical patent/NO981135D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen tilveiebringer en serie av krystallinske salter av (S)- (+)-8-klor-5-(5,6-diklor-2,3-di- hydrobenzofuran-7-yl)-3-metyl-2,3,4,5- tetrahydro-lH-3-benzazepin-7-ol, deres fremstilling og anvendelse som terapeu- tiske midler.
NO981135A 1995-09-15 1998-03-13 Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser NO981135D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK103095 1995-09-15
PCT/DK1996/000383 WO1997010239A1 (en) 1995-09-15 1996-09-12 Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds

Publications (2)

Publication Number Publication Date
NO981135L true NO981135L (no) 1998-03-13
NO981135D0 NO981135D0 (no) 1998-03-13

Family

ID=8100205

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981135A NO981135D0 (no) 1995-09-15 1998-03-13 Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser

Country Status (13)

Country Link
EP (1) EP0850237A1 (no)
JP (1) JPH11512403A (no)
KR (1) KR19990044648A (no)
CN (1) CN1200121A (no)
AU (1) AU700596B2 (no)
BR (1) BR9610162A (no)
CA (1) CA2231848A1 (no)
CZ (1) CZ77898A3 (no)
HU (1) HUP9900746A3 (no)
IL (1) IL123602A0 (no)
NO (1) NO981135D0 (no)
PL (1) PL325514A1 (no)
WO (1) WO1997010239A1 (no)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK23392D0 (da) * 1992-02-24 1992-02-24 Novo Nordisk As Heterocykliske forbindelser, deres anvendelse og fremstilling

Also Published As

Publication number Publication date
AU6923596A (en) 1997-04-01
WO1997010239A1 (en) 1997-03-20
JPH11512403A (ja) 1999-10-26
IL123602A0 (en) 1998-10-30
MX9802000A (es) 1998-08-30
EP0850237A1 (en) 1998-07-01
CN1200121A (zh) 1998-11-25
HUP9900746A3 (en) 1999-11-29
CZ77898A3 (cs) 1998-07-15
HUP9900746A2 (hu) 1999-09-28
NO981135D0 (no) 1998-03-13
BR9610162A (pt) 1999-01-05
AU700596B2 (en) 1999-01-07
CA2231848A1 (en) 1997-03-20
KR19990044648A (ko) 1999-06-25
PL325514A1 (en) 1998-08-03

Similar Documents

Publication Publication Date Title
MX9605741A (es) Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
SE9504661D0 (sv) New compounds
BG102259A (en) Compostions with controlled paroxetine release
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
AU5313496A (en) Nodulisporic acid derivatives
NO996108L (no) 9-oksinerytromycinderivater
PT998287E (pt) Utilizacao de levobupivacaina
DE69521122D1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
DK0744397T3 (da) Fluorphenylsubstituerede alkenylcarboxylsyre-guanidiner som Na+/K+-antiport-inhibitorer, deres anvendelse som lægemiddel el
NO964348L (no) CCK- eller gastrin-modulerende 5-hetrocykliske-1,5-benzodiazepiner
EP1008345A4 (en) ANTI-ALLERGIC AGENTS
IT1306147B1 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
NO981135L (no) Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser
DK0934342T3 (da) Præparat indeholdende chitosan
BR9809286A (pt) Processos para redução de fibrinogênio
BR9712805A (pt) Processo para a preparação de compostos farmecêuticos
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
DK0967986T3 (da) Anvendelse af humant alfa1-surt glycoprotein til fremstilling af et farmaceutisk præparat